Medical Oncology · 2014 · 116 citations · 20 references
MedicineOncologyPathologyMolecular OncologyNeoplasiaOncogenesCancer BiomarkersCancer MetabolismMalignant NeoplasmsMolecular Tumor ProfilingOvarian CancerTumor MarkersFigo StagingHer2 ExpressionMalignant Ovarian NeoplasmsMicroarray AnalysisOvarian Cancer BiomarkersOvarian Cancer Prognostic BiomarkersOvarian Tumor BiomarkersTissue Microarray Analysis
The present study was designed to explore the cross talk between fatty acid synthase (FASN) and HER2 (ErbB2) in ovarian cancer. A total of 60 ovarian cancer patients and 15 normal ovarian tissues were enrolled. Tissue array was conducted by using a tissue microarray instrument. Immunohistochemistry was performed to quantify the expressions of HER2 and FASN. The FASN was detected to be distributed in the cell cytoplasm and was significantly correlated with cancer grade (p = 0.000) and FIGO staging (p = 0.000). Patients with FASN overexpression in ovarian cancer tend to have a worse overall survival rate (p = 0.000). HER2 was also stained to be distributed in the cell cytoplasm associated with higher expression in high-grade cancer. It was also disclosed that FASN expression level is not correlated with HER2 status in ovarian cancer. These results for the first time indicated that a cross talk in FASN and HER2 expressions might be associated with prognosis in malignant ovarian cancer.
20
Javier A. Menéndez, Luciano Vellón, Inderjit Mehmi et al. · Proceedings of the National Academy of Sciences · 2004 · 325 citations · Full text
Fatty acid synthase expression defines distinct molecular signatures in prostate cancer.
Sabrina Rossi, Edgard Graner, Phillip G. Febbo et al. · PubMed · 2003 · 304 citations
Basic science of HER-2/neu: a review.
Mien‐Chie Hung, Y.K. James Lau · PubMed · 1999 · 267 citations